Gastrointestinal Cancer

A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified him on the patient journey and enhancing their quality of care.

In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.

The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.

Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.

James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.

The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions.

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Suneel Kamath, MD, shares insights on targeted therapies in pancreatic cancer after an X Takeover with OncLive during Pancreatic Cancer Awareness Month.

Suneel Kamath, MD, took to the OncLive X (Twitter) account during Pancreatic Cancer Awareness Month to share the importance of recognizing this disease.

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.

Nataliya Uboha, MD, PhD, and Robert Albert Anders, MD, PhD, unpack the unfavorable risk-benefit profile of PD-1 inhibitors in patients with certain PD-L1–negative gastrointestinal cancers and discussions from a recent ODAC meeting.

China's NMPA has accepted a sNDA for penpulimab plus anlotinib for the first-line treatment of advanced hepatocellular carcinoma.

The FDA approved the PATHWAY HER2 (4B5) test to identify patients with HER2-positive biliary tract cancer who are eligible for treatment with zanidatamab.

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

James J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.

The FDA has granted accelerated approval to zanidatamab for pretreated, advanced HER2-positive biliary tract cancer.

Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.

Tanios S. Bekaii-Saab, MD, discusses the role of liquid biopsies and ctDNA in gastrointestinal cancers.